Targeting MET in cancer: rationale and progress
E Gherardi, W Birchmeier, C Birchmeier… - Nature reviews …, 2012 - nature.com
Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …
The molecular biology of head and neck cancer
CR Leemans, BJM Braakhuis, RH Brakenhoff - Nature reviews cancer, 2011 - nature.com
Head and neck squamous cell carcinomas (HNSCCs) are caused by tobacco and alcohol
consumption and by infection with high-risk types of human papillomavirus (HPV). Tumours …
consumption and by infection with high-risk types of human papillomavirus (HPV). Tumours …
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and …
JJ Cui, M Tran-Dubé, H Shen, M Nambu… - Journal of medicinal …, 2011 - ACS Publications
Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor
tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal …
tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal …
Targeting adaptive glioblastoma: an overview of proliferation and invasion
Glioblastoma is one of the most devastating cancers, in which tumor cell infiltration into
surrounding normal brain tissue confounds clinical management. This review describes …
surrounding normal brain tissue confounds clinical management. This review describes …
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer
JP Eder, GF Vande Woude, SA Boerner… - Clinical Cancer …, 2009 - AACR
A wide variety of human malignancies exhibit sustained c-Met stimulation, overexpression,
or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid …
or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid …
MET: a promising anticancer therapeutic target
S Peters, AA Adjei - Nature reviews Clinical oncology, 2012 - nature.com
The MET pathway is dysregulated in many human cancers and promotes tumour growth,
invasion and dissemination. Abnormalities in MET signalling have been reported to …
invasion and dissemination. Abnormalities in MET signalling have been reported to …
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Selective small-molecule kinase inhibitors have emerged over the past decade as an
important class of anti-cancer agents, and have demonstrated impressive clinical efficacy in …
important class of anti-cancer agents, and have demonstrated impressive clinical efficacy in …
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
TR Webb, J Slavish, RE George, AT Look… - Expert review of …, 2009 - Taylor & Francis
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor
superfamily, was initially identified in constitutively activated oncogenic fusion forms–the …
superfamily, was initially identified in constitutively activated oncogenic fusion forms–the …
[HTML][HTML] Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies
Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …
Decorin is a novel antagonistic ligand of the Met receptor
Decorin, a member of the small leucine-rich proteoglycan gene family, impedes tumor cell
growth by down-regulating the epidermal growth factor receptor. Decorin has a complex …
growth by down-regulating the epidermal growth factor receptor. Decorin has a complex …